Hansen Gwenn 4

What Happened
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), received equity awards on February 10, 2026 totaling 136,625 derivative shares: 93,750 shares under a stock option grant and 42,875 restricted stock units (RSUs). Both grants were reported at $0.00 consideration (standard for awards), meaning no cash was paid by the insider at grant. These are awards for future vesting, not open‑market purchases or sales.

Key Details

• Transaction date: 2026-02-10; transaction code A (award/grant). Report filed with period 2026-02-10 (no late filing indicated in provided data).
• Award breakdown: 93,750 option shares (derivative) and 42,875 RSUs (derivative); combined = 136,625 awards. Reported price: $0.00.
• Vesting — options (footnote F1): vest 1/36th monthly beginning March 10, 2026, through Feb 9, 2029, subject to continued service.
• Vesting — RSUs (footnotes F2–F4): each RSU converts to one share on vesting; RSUs vest 1/12th quarterly over three years, first vesting on July 30, 2026; RSUs do not expire.
• Shares owned after the transaction: not provided in the supplied filing details.
• No immediate sale or exercise reported — these are future vesting awards (not a cashless exercise or open‑market trade).

Context

• Options and RSUs are common executive compensation tools: RSUs become actual shares as they vest; options give the right to buy shares later (exercise would be reported separately).
• Because these are grants (not purchases or sales), they do not by themselves signal buying or selling intent; they reflect compensation subject to service‑based vesting conditions.